← Back to Search

Other

CC-94676 for Metastatic Castration-Resistant Prostate Cancer

Phase 1
Recruiting
Research Sponsored by Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must have histologically or cytologically confirmed adenocarcinoma of the prostate
Must have Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 4 years
Awards & highlights

Study Summary

This trial is testing a new drug for men with prostate cancer that has spread and is resistant to hormone therapy.

Who is the study for?
Men with advanced prostate cancer that has spread and is resistant to hormone therapy can join this trial. They must have tried at least one other treatment for their condition, be in good physical shape (able to perform daily activities without significant limitations), and not have any other active cancers or recent serious blood clots.Check my eligibility
What is being tested?
The study tests the safety and initial effectiveness of three experimental drugs: CC1083610, CC1083611, and CC-94676. These are given to men whose prostate cancer has worsened despite hormone therapy and previous treatments.See study design
What are the potential side effects?
Possible side effects include typical reactions from cancer medications such as nausea, fatigue, allergic responses, changes in blood counts leading to increased infection risk or bleeding problems. Specific side effects will depend on each drug's profile.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate cancer diagnosis was confirmed through a lab test.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My prostate cancer has worsened despite hormone therapy and at least one other treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose-limiting toxicity (DLT)
Maximum tolerated dose (MTD)
Non-tolerated dose (NTD)
+1 more
Secondary outcome measures
Complement H50
Duration of response (DOR)
Objective soft tissue response defined by complete response (CR) or partial response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3)
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Administration of CC-94676, CC1083611, and CC1083610Experimental Treatment3 Interventions

Find a Location

Who is running the clinical trial?

CelgeneLead Sponsor
636 Previous Clinical Trials
128,604 Total Patients Enrolled
5 Trials studying Prostate Cancer
1,270 Patients Enrolled for Prostate Cancer
Marie Nguyen, MDStudy DirectorCelgene
3 Previous Clinical Trials
141 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,507 Previous Clinical Trials
3,369,630 Total Patients Enrolled
13 Trials studying Prostate Cancer
3,921 Patients Enrolled for Prostate Cancer

Media Library

CC-94676 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04428788 — Phase 1
Prostate Cancer Research Study Groups: Administration of CC-94676, CC1083611, and CC1083610
Prostate Cancer Clinical Trial 2023: CC-94676 Highlights & Side Effects. Trial Name: NCT04428788 — Phase 1
CC-94676 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04428788 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent has recruitment for this clinical experiment been successful?

"This medical trial necessitates 122 participants that meet the qualifications. Potential volunteers can join from Sibley Memorial Hospital in Washington, D.C., and UAB in Birmingham, Alabama."

Answered by AI

Is CC-94676 a reliable option for patient treatment?

"The safety of CC-94676 is rated as 1 due to its current Phase 1 status; this signifies that only limited data exists for both efficacy and safety."

Answered by AI

Is the enrollment period for this trial still open?

"The clinicaltrials.gov database confirms that this medical trial is recruiting patients at present, with the original post dated June 22nd 2020 and the last editing occuring on December 1st 2022."

Answered by AI

How widespread are the implementations of this experiment in Canada?

"Sibley Memorial Hospital in Washington D.C., UAB in Birmingham, Alabama and Florida Cancer Specialists in Sarasota, FL are all hosting participating sites for this medical trial alongside 23 other clinical locations."

Answered by AI

Who else is applying?

What state do they live in?
Georgia
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
2020. "Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04428788.
All > Prostate Cancer Boston > Prostate Cancer
~58 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top